<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45188">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01861626</url>
  </required_header>
  <id_info>
    <org_study_id>V00057 CA 1 01</org_study_id>
    <secondary_id>2013-000988-80</secondary_id>
    <nct_id>NCT01861626</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of V0057 Versus a Reference Formulation After Single Administration in Healthy Male Subjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pierre Fabre Dermatology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pierre Fabre Dermatology</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Germany: Ethics Commission</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the bioequivalence (comparison of the rate and
      extent of the active substance into the body following single administration of the drugs)
      between the test product V0057  and a reference product after two single oral administration
      separate by 7 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>18 time points up to 72h after administration</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of Maximum Concentration (Tmax)</measure>
    <time_frame>18 time points up to 72h after administration</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under curve (AUC0-72)</measure>
    <time_frame>18 time points up to 72h after administration</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>sequence 1 : Test drug - Reference</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2 : Reference - Test drug</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>V0057 - A mg</intervention_name>
    <description>Single oral administration</description>
    <arm_group_label>sequence 1 : Test drug - Reference</arm_group_label>
    <arm_group_label>Sequence 2 : Reference - Test drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotretinoin</intervention_name>
    <description>Single oral administration</description>
    <arm_group_label>sequence 1 : Test drug - Reference</arm_group_label>
    <arm_group_label>Sequence 2 : Reference - Test drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subject aged 18 to 50 years (inclusive)

        Exclusion Criteria:

          -  Presence of any significant medical finding or significant history that may impact
             the safety, the interpretation of the results and/or the participation of the subject
             in the study according to the opinion of the investigator

          -  Presence of any clinically significant abnormal finding at examination in the
             Investigator's opinion
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Erfurt</city>
        <zip>D-99084</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 18, 2013</lastchanged_date>
  <firstreceived_date>May 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Isotretinoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
